Kyverna Therapeutics (KYTX) Cash & Equivalents (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash & Equivalents data on file, last reported at $28.7 million in Q1 2026.

• Quarterly Cash & Equivalents fell 49.53% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.7 million (down 49.53% YoY) and the FY2025 annual result came in at $124.1 million, up 28.43% from the prior year.
• Cash & Equivalents retreated to $28.7 million in Q1 2026, from $124.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $224.3 million in Q1 2024 to a low of $23.0 million in Q3 2023.
• A 4-year average of $77.2 million and a median of $53.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 463.73% — and 2025, when it slumped 74.65%.
• Tracing KYTX's Cash & Equivalents over 4 years: stood at $34.6 million in 2023, then surged by 178.87% to $96.6 million in 2024, then increased by 28.43% to $124.1 million in 2025, then tumbled by 76.87% to $28.7 million in 2026.
• The last three Cash & Equivalents figures came in at $28.7 million (Q1 2026), $124.1 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.